Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Background— Experimental studies revealed proinflammatory properties of angiotensin II. We evaluated antiinflammatory effects of the angiotensin II subtype 1 receptor antagonist olmesartan medoxomil alone and in cotherapy with the HMG-CoA reductase inhibitor pravastatin in patients with essential hypertension and microinflammation. Methods and Results— We measured a panel of vascular inflammation markers, including high-sensitivity C-reactive protein, and lipid levels during 12 weeks of therapy with olmesartan (n=100) or placebo (n=99) in a prospective double-blind multicenter study. Pravastatin was added to the double-blind therapy at week 6 in both treatment arms. Blood pressure control was achieved with addition of hydrochlorothiazide. Olmesartan treatment had already significantly reduced serum levels of high-sensitivity C-reactive protein (−15.1%; P <0.05), high-sensitivity tumor necrosis factor-α (−8.9%; P <0.02), interleukin-6 (−14.0%; P <0.05), and monocyte chemotactic protein-1 (−6.5%; P <0.01) after 6 weeks of therapy, whereas placebo treatment (ie, blood pressure reduction) had no major effect on inflammation markers. After 12 weeks of therapy, high-sensitivity C-reactive protein (−21.1%; P <0.02), high-sensitivity tumor necrosis factor-α (−13.6%; P <0.01), and interleukin-6 (−18.0%; P <0.01) decreased further with olmesartan and pravastatin cotherapy, but treatment with pravastatin alone (ie, cotherapy with placebo) did not significantly alter inflammation markers. In contrast, addition of pravastatin led to a significant ( P <0.001) reduction in LDL cholesterol serum concentrations in the olmesartan and placebo treatment groups (−15.1% and −12.1%, respectively). Conclusions— Angiotensin II receptor blockade significantly reduces vascular microinflammation in patients with essential hypertension by as early as week 6 of therapy. This antiinflammatory action of angiotensin II receptor antagonists may contribute to their beneficial cardiovascular effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734 · cited 2×
“В кардиологии наибольшее внимание уделяется вчСРБ — важному предиктору риска будущих ССС в различных клинических популяциях [2,7-11].”
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850 · cited 1×
“Как предиктор ССР, вчСРБ превосходил целый ряд воспалительных и липидных маркеров при их непосредственном сравнении [12].”
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513 · cited 5×
“Ассоциация между СРБ и ССР может носить дозозависимый характер: у лиц с уровнями вчСРБ 1-3 мг/л риск расценивается как средний, а у лиц с концентрацией вчСРБ >3 мг/л — как высокий [2, 9].”
InfluentialDirect Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells
Pasceri, V., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.102.18.2165 · Cited by 1,940
Cited by
Murphy, S. P., Kakkar, R., McCarthy, C. P., & Januzzi, J. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.014 · Cited by 738
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Renin-angiotensin system and cardiovascular risk
Schmieder, R. E., Hilgers, K. F., Schlaich, M. P., & Schmidt, B. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60242-6 · Cited by 663
Is atrial fibrillation an inflammatory disorder?
Boos, C. J., Anderson, R. A., & Lip, G. Y. H. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi645 · Cited by 552
Structural and Functional Remodeling of the Left Atrium
Casaclang-Verzosa, G., Gersh, B. J., & Tsang, T. S. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.026 · Cited by 529
Ferrario, C. M., & Strawn, W. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.059 · Cited by 512
Srikanthan, K., Feyh, A., Visweshwar, H., Shapiro, J. I., & Sodhi, K. (2016) · International Journal of Medical Sciences · doi:10.7150/ijms.13800 · Cited by 443
The effects of hypertension on the cerebral circulation
Pires, P. W., Dams Ramos, C. M., Matin, N., & Dorrance, A. M. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00490.2012 · Cited by 408
Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity
Donath, M. Y., Dalmas, É., Sauter, N. S., & Böni-Schnetzler, M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.001 · Cited by 338
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 332
Inflammation and vitamin D: The infection connection
Mangin, M., Sinha, R., & Fincher, K. (2014) · Inflammation Research · doi:10.1007/s00011-014-0755-z · Cited by 274
“els of inflammatory markers; h-CRP, h-TNFa, IL-6, MCP-1 after 6 weeks of therapy [166].”
BackgroundC‐Reactive Protein (CRP)‐Lowering Agents
Prasad, K. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00033.x · Cited by 272
Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
Pollack, R. M., Donath, M. Y., LeRoith, D., & Leibowitz, G. (2016) · Diabetes Care · doi:10.2337/dcs15-3015 · Cited by 262
Bahlmann, F. H., de Groot, K., Mueller, O., Hertel, B., Haller, H., & Fliser, D. (2005) · Hypertension · doi:10.1161/01.hyp.0000159191.98140.89 · Cited by 259
Self-citationStrain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk
Ito, S., Nagasawa, T., Abe, M., & Mori, T. (2009) · Hypertension Research · doi:10.1038/hr.2008.27 · Cited by 246
NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases
Fiordelisi, A., Iaccarino, G., Morisco, C., Coscioni, E., & Sorriento, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071599 · Cited by 215
“Additionally, the treatment with Angiotensin II receptor blockade reduces the levels of CRP, TNFα, IL-6, and MCP-1 in patients with essential hypertension [66].”
BackgroundC-reactive protein and Hypertension
Hage, F. G. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2013.111 · Cited by 205
Role of self-care in the patient with heart failure
Moser, D. K., Dickson, V., Jaarsma, T., Lee, C., Stromberg, A., & Riegel, B. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0267-9 · Cited by 186
Is Hypertension an Inflammatory Process?
Boos, C., & Lip, G. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776843313 · Cited by 165
McMurray, J., Solomon, S., Pieper, K., Reed, S., Rouleau, J., Velazquez, E., White, H., Howlett, J., Swedberg, K., Maggioni, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.055 · Cited by 159
Renal and vascular hypertension-induced inflammation: role of angiotensin II
Ruiz-Ortega, M., Esteban, V., Rupérez, M., Sánchez-López, E., Rodríguez-Vita, J., Carvajal, G., & Egido, J. (2006) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000203190.34643.d4 · Cited by 158
Living Well With Medical Comorbidities: A Biopsychosocial Perspective
Friedman, E. M., & Ryff, C. D. (2012) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/gbr152 · Cited by 156
Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD
Poznyak, A. V., Bharadwaj, D., Prasad, G., Grechko, A. V., Sazonova, M. A., & Orekhov, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136702 · Cited by 142
“Atherosclerosis is a serious health problem due to its relation to cardiovascular disease, which is one of the leading causes of death around the globe.”
BackgroundInfluentialSavoia, C., Volpe, M., Alonzo, A., Rossi, C., & Rubattu, S. (2010) · Clinical Science · doi:10.1042/cs20090204 · Cited by 35
Metadata
- Authors
- Fliser, D., Buchholz, K., & Haller, H.
- Venue
- Circulation
- Published
- 2004-08-31
- Volume
- 110
- Issue
- 9
- Pages
- 1103-1107
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2152043519
- Cited by
- 404
- References
- 36
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.